- Home
- PKG vs ROIV Comparison
PKG vs ROIV Comparison
Compare PKG & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PKG | ROIV |
|---|---|---|
| Founded | 1867 | 2014 |
| Country | United States | United Kingdom |
| Employees | 13600 | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7B | 26.1B |
| IPO Year | 1999 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PKG | ROIV |
|---|---|---|
| Price | $250.86 | $37.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $232.38 | $28.94 |
| AVG Volume (30 Days) | 661.0K | ★ 5.4M |
| Earning Date | 04-22-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.05 | N/A |
| Revenue | ★ $8,989,300,000.00 | $8,260,000.00 |
| Revenue This Year | $13.32 | N/A |
| Revenue Next Year | $4.61 | $744.61 |
| P/E Ratio | $62.46 | ★ N/A |
| Revenue Growth | ★ 7.23 | N/A |
| 52 Week Low | $191.50 | $11.54 |
| 52 Week High | $259.98 | $37.19 |
Technical Indicators
Market Signals| Indicator | PKG | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 64.31 |
| Support Level | $202.02 | $27.15 |
| Resistance Level | $258.81 | N/A |
| Average True Range (ATR) | 5.14 | 1.24 |
| MACD | -0.69 | 0.15 |
| Stochastic Oscillator | 52.03 | 97.01 |
Price Performance
Historical ComparisonAbout PKG Packaging Corporation of America
Packaging Corp. of America is the third-largest containerboard and corrugated packaging manufacturer in the United States. It produces over 5 million tons of containerboard annually. The company's share of the domestic containerboard market is roughly 10%. PCA differentiates itself from larger competitors by focusing on smaller customers and operating with a high degree of flexibility.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.